The DOI matches its Crossref record.
Safety and tolerability of intradiscal implantation of combined autologous adipose-derived mesenchymal stem cells and hyaluronic acid in patients with chronic discogenic low back pain: 1-year follow-up of a phase I study
Open accessAbstract
Adipose tissue-derived mesenchymal stem cells (AT-MSCs) offer potential as a therapeutic option for chronic discogenic low back pain (LBP) because of their immunomodulatory functions and capacity for cartilage differentiation. The goal of this study was to assess the safety and tolerability of a single intradiscal implantation of combined AT-MSCs and hyaluronic acid (HA) derivative in patients with chronic discogenic LBP. We performed a single-arm phase I clinical trial with a 12-month follow-up and enrolled 10 eligible chronic LBP patients. Chronic LBP had lasted for more than 3 months with a minimum intensity of 4/10 on a visual analogue scale (VAS) and disability level ≥ 30% on the Oswestry Disability Index (ODI). The 10 patients underwent a single intradiscal injection of combined HA derivative and AT-MSCs at a dose of 2 × 107 cells/disc (n = 5) or 4 × 107 cells/disc (n = 5). Safety and treatment outcomes were evaluated by assessing VAS, ODI, Short Form-36 (SF-36), and imaging (lumbar spine X-ray imaging and MRI) at regular intervals over 1 year. No patients were lost at any point during the 1-year clinical study. We observed no procedure or stem cell-related adverse events or serious adverse events during the 1-year follow-up period. VAS, ODI, and SF-36 scores significantly improved in both groups receiving both low (cases 2, 4, and 5) and high (cases 7, 8, and 9) cell doses, and did not differ significantly between the two groups. Among six patients who achieved significant improvement in VAS, ODI, and SF-36, three patients (cases 4, 8, and 9) were determined to have increased water content based on an increased apparent diffusion coefficient on diffusion MRI. Combined implantation of AT-MSCs and HA derivative in chronic discogenic LBP is safe and tolerable. However, the efficacy of combined AT-MSCs and HA should be investigated in a randomized controlled trial in a larger population. ClinicalTrials.gov NCT02338271 . Registered 7 January 2015.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Mesenchymal Stem Cells for Regenerative Medicine
Han, Y., Li, X., Zhang, Y., Han, Y., Chang, F., & Ding, J. (2019) · Cells · doi:10.3390/cells8080886 · Cited by 1,093
Joyce, K., Fabra, G. T., Bozkurt, Y., & Pandit, A. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00512-8 · Cited by 316
Cell-based strategies for IVD repair: clinical progress and translational obstacles
Binch, A. L. A., Fitzgerald, J. C., Growney, E. A., & Barry, F. (2021) · Nature Reviews Rheumatology · doi:10.1038/s41584-020-00568-w · Cited by 296
Wu, P. H., Kim, H. S., & Jang, I.-T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21062135 · Cited by 266
Kim, J. H., Kwon, T.-R., Lee, S. E., Jang, Y. N., Han, H. S., Mun, S. K., & Kim, B. J. (2020) · Scientific Reports · doi:10.1038/s41598-020-61952-w · Cited by 53
Self-citation
Metadata
- Authors
- Kumar, H., Ha, D.-H., Lee, E.-J., Park, J. H., Shim, J. H., Ahn, T.-K., Kim, K.-T., Ropper, A. E., Sohn, S., Kim, C.-H., Thakor, D. K., Lee, S.-H., & Han, I.-B.
- Venue
- Stem Cell Research & Therapy
- Published
- 2017-11-15
- Volume
- 8
- Issue
- 1
- Pages
- 262-262
- ISSN
- 1757-6512 (ISSN-L)
- OpenAlex
- W2771006532
- Cited by
- 213
- References
- 0
- FWCI
- 10.57
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety and tolerability of intradiscal implantation of combined autologous adipose-derived mesenchymal stem cells and hyaluronic acid in patients with chronic discogenic low back pain: 1-year follow-up of a phase I study. https://app.cochat.ai/papers/10.1186/s13287-017-0710-3
- The paper
- Kumar, H., Ha, D.-H., Lee, E.-J., Park, J. H., Shim, J. H., Ahn, T.-K., Kim, K.-T., Ropper, A. E., Sohn, S., Kim, C.-H., Thakor, D. K., Lee, S.-H., & Han, I.-B. (2017). Safety and tolerability of intradiscal implantation of combined autologous adipose-derived mesenchymal stem cells and hyaluronic acid in patients with chronic discogenic low back pain: 1-year follow-up of a phase I study. Stem Cell Research & Therapy. https://doi.org/10.1186/s13287-017-0710-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.